Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER_GOV 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

NET 2Gastrointestinal 2Endocrine 2Thoracic 1Sarcoma 1Other solid neoplasm 1Gynecologic 1CNS 1

Conditions

Carcinoma, Neuroendocrine 5Neuroendocrine Tumors 2Neoplasms 2Lung Neoplasms 2Gastro-enteropancreatic neuroendocrine tumor 2Carcinoma, Ovarian Epithelial 2Vipoma 1Stomach Neoplasms 1Somatostatinoma 1Small Cell Lung Carcinoma 1Sarcoma 1Pancreatic Neoplasms 1Neoplasms, Unknown Primary 1Neoplasm Metastasis 1Mesothelioma 1Insulinoma 1Glucagonoma 1Glioblastoma 1Gastrointestinal Neoplasms 1Gastrinoma 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Small Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1Carcinoma, Islet Cell 1Adenoma, Islet Cell 1

Interventions

lutetium Lu 177 dotatate 8lanreotide 4copper dotatate CU-64 4Octreotide 4177Lu-octreotide, DOTA(0)-Tyr(3)- 4pasireotide 3Magnetic Resonance Spectroscopy 3Lutetium-177 3Lutetium 3gallium Ga 68 dotatate 2amino-acid, glucose, and electrolyte solution 2Temozolomide 2Nivolumab 2Irinotecan 2Ga(III)-DOTATOC 2Everolimus 2Etoposide 2Carboplatin 2zimberelimab 1regorafenib 1pembrolizumab 1irinotecan sucrosofate 1folfirinox 1famitinib 1cabozantinib 1arginyllysine 1abemaciclib 1X-Rays 1Sunitinib 1Somatostatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Gastro-enteropancreatic neuroendocrine tumor × Irinotecan × Endocrine × Clear all
NCT02611024 2025-07-09

Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors

PharmaMar

Phase 1/2 Completed
316 enrolled
CNSEndocrineGastrointestinalGynecologicNETOther solid neoplasmSarcomaThoracic

Gastro-enteropancreatic neuroendocrine tumor, Carcinoma, Ovarian Epithelial, Glioblastoma, Mesothelioma, Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Neuroendocrine Tumors

NCT03963193 2019-05-24

Etoposide/Cisplatin Compared With Irinotecan/Cisplatin for Advanced Gastrointestinal Neuroendocrine Tumor G3 Type

Henan Cancer Hospital

Phase 2 Unknown
112 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡